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 Introduction                                                                                          
Diabetes is a metabolic disease that leads to high blood sugar due 
to either insulin insufficiency, insulin resistance or both.1 According 
to the World Health Organization at least 171 million people (2.8% 
of the world population) suffered from diabetes in year 2000.1 This 
number will almost double by year 2030.1
It is expected that more than 70% of total diabetic patients in 
the world will be from developing countries by year 2030.2 The 
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 Abstract                                                                                                            
Background:  The dramatic increase in the incidence of diabetes 
and its associated complications require a natural and safe solution 
to control and delay such complications. The present study tested 
the hypothesis that probiotics may affect biochemical indices of 
diabetic patients 
Methods: Thirty four types 2 diabetic patients aged between 25 
to 65 years, and diagnosed with diabetes for less than 15 years 
were selected for this single- blinded clinical trial. Using balanced 
block random sampling, the patients were divided into two groups 
of intervention (probiotics) and placebo. Blood samples tested for 
baseline glucose, insulin, TG, total cholesterol, LDL-C, HDL-C, 
malondialdehyde, high sensitive CRP (hs-CRP) and IL-6. After 
six weeks of experiment, fasting blood samples were re-tested 
and the data obtained were analyzed using SPSS software. 
Results: There were no significant differences between 
anthropometric data including body mass index and waist to hip 
ratio  in placebo and treatment groups. There was no significant 
difference in FBS, Serum TG concentration total cholesterol and 
LDL-C levels between placebo and treatment groups. HDL-C 
levels were slightly elevated after probiotic treatment, which were 
not statistically significant. Insulin, MDA and IL-6 levels were 
reduced and high sensitive CRP hs.CRP levels were elevated, 
although, not statistically significant. 
Conclusion: The result of this study indicates a non- significant 
declining trend in the level of TG, MDA and IL-6 and insulin 
resistance after consumption of probiotics. 
Please cite this article as: Mazloom Z, Yousefinejad A, Dabaghmanaesh MH. 
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prevalence of type 2 diabetes in Iran ranges 
from 1.3% to 14.5% which will increase as the 
population ages in both males (10.6%) and 
females (11.3%).2
Vascular diseases are one of the most common 
causes of morbidity and mortality in diabetic 
patients.3 Although, there is positive relation 
between insulin resistance and vascular disease,4 
the exact mechanisms by which diabetes leads to 
arthrosclerosis is not well- understood. Numerous 
studies have documented a role for inflammation 
in atherosclerosis.5 C-reactive protein (CRP) and 
interleukin 6 (IL-6) the two most sensitive markers 
of inflammation have been elevated in patients 
with type 2 diabetes.6 In addition, high CRP level 
is shown to be a risk factor for developing  type 
2 diabetes, which may be atherogenic.7
Hyperglycemia is also consistently associated 
with increased oxidative stress. Oxidative stress 
is a component of cellular damage and has an 
important role in the pathogenesis of a number 
of human diseases including atherosclerosis. 
Mechanisms that contribute to increased oxidative 
stress in diabetes may include not only increased 
non-enzymatic glycosylation and auto-oxidative 
glycosylation but also to decreasing antioxidant 
defence potential.8
FAO/WHO, define probiotics as live 
microorganisms which when administered 
in adequate amounts confer a health benefit 
on the host.9 Lactic acid bacteria (LAB) and 
bifidobacteria are the most common types of 
microbes used as probiotics. Animal studies 
showed that Lactobacillus GG treatment not only 
reduces glucose intolerance but also significantly 
decrease hyperglycemia in streptozotocin 
induced diabetes rats.10
Among other beneficial effects of probiotics 
and prebiotics, the reduction of blood lipids is of 
particular interest.5 Lactobacilli and bifidobacteria 
are the primary probiotic bacteria which are 
associated with cholesterol reduction, although 
comparable effect may be produced by other 
lactic acid bacteria, such as enterococci.11 It has 
also been reported that oral administration of heat 
killed Lactobacillus casei to non-obese diabetic 
(NOD) mice reduces the incidence of diabetes, 
but the mechanism underlying this effect has not 
been clarified.12,13
This study was designed to determine the 
effect of probiotics on lipid profile, glycemic 
control, insulin level, oxidative stress and 
inflammatory markers in patients with type 2 
diabetes. 
 Patients and Methods                                                                                       
This single-blinded clinical trial comprised 40 
patients with type 2 diabetes recruited from 
medical clinic affiliated with Shiraz University of 
Medical Sciences (SUMS) Shiraz Iran. Diabetic 
patients with fasting blood glucose ≥126 mg/dl, 
aged from 25 to 65 years, and diagnosed as having 
diabetes for less than 15 years were eligible for the 
study. Exclusion criteria were current smokers, 
subjects on non-steroidal anti-inflammatory drugs 
and multivitamin, as well as patients undergoing 
hormone replacement therapy, and those with any 
chronic diseases involving kidney, liver, and lung. 
The research was approved by the Ethics committee 
of SUMS, and written informed consent was 
obtained from all patients prior to commencement 
of the study. Subjects were initially studied during 
a screening visit 
Study Design
After an overnight fast starting from 8 pm 
in previous evening baseline plasma samples 
were collected and analyzed for triglyceride, 
total cholesterol, LDL-C, HDL-C, glucose, 
insulin, malondialdehyde, hs-CRP and IL-6. 
Using balanced block random sampling, 
subjects were then divided into two groups of 
intervention (probiotics) and placebo. Patients in 
the intervention or treatment group received 1500 
mg probiotic capsules twice daily, after lunch 
and evening meal for 6 weeks. The lactobacillus 
probiotics contained L. acidophilus, L. bulgaricus, 
L. bifidum, and L. casei. Patients in placebo group 
received 1500 mg capsules containing 1000 mg 
magnesium stearate twice daily for six weeks. 
Magnesium stearate is generally considered safe 
for human consumption at levels below 2500 mg/
kg per day.14 According to the FDA’s subcommittee 
report on GRAS (generally recognized as safe) 
substances (SCOGS), adding magnesium 
stearate directly to human food was affirmed as 
GRAS.15 After six weeks of experiment, fasting 
blood samples were collected and analyzed for 
all aforementioned parameters. 
Methods of Data Gathering
Demographic data including age, sex, 
weight, height, body mass index (BMI), and 
waist to hip ratio (WHR) were measured before 
and after the intervention. Auto-analyzer Bio-
Systems A-25 was used to determine the lipid 
profile and blood glucose concentration. ELISA 
method was employed to determine insulin 
levels, high sensitive CRP (hsCRP) and IL-6. 
Spectrophotometric method was used for 
determining the level of malondialdehyde (MDA).
Statistical Analysis
SPSS software, version 16 was used to test the 
data. Paired samples t test was used to compare 
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continuous variables within groups. Comparison 
between different groups was performed through 
two independent samples t-test. In the absence of 
normal distribution, comparison between groups 
was made using non-parametric Wilcoxon on 
signed ranks and Mann-Whitney tests. P values 
<0.05 was considered significant. 
 Results                                                                                       
The study was conducted on 34 patients, of which 26 
were females and 8 males. Patients’ characteristics 
are shown in table 1. The mean age in the placebo 
and treatment groups were 51.8±10.2 and 55.4±8 
respectively. There were no significant differences 
in BMI and WHR between placebo and treatment 
groups (table 1).
Table 2 shows changes in biochemical 
markers after probiotic treatment. The fasting 
blood sugar did not change significantly after 
probiotic treatment (table2). Serum triglyceride 
concentration was reduced in probiotic treated 
group but the change was not significant (table2). 
There were no significant differences in total serum 
cholesterol, LDL-C, and HDL-C levels, between 
probiotic and placebo groups (table2). Fasting 
plasma insulin level did not change in probiotic 
group compared to placebo group (table2). 
Although MDA and IL-6 levels were reduced 
in treatment group, but the changes were not 
statistically significant (table 2). There were 
an increase in CRP levels in treatment group 
compared to placebo, but the change was not 
significant (table2).
Insulin-sensitivity was determined through 
quantitative insulin sensitivity check index 
(QUICKI) and insulin-resistance by HOMA IR, 
FIRI, Bennett’s Index and Ins/gluc ratio but there 
were no significant changes in these indices 
(table 2).
 Discussion                                                                                       
Diabetic complication, such as cardiovascular 
disease on the one hand and the dramatic growth 
of diabetic incidence on the other, demands a 
Table1: The mean anthropometric data in the placebo and treatment groups
Parameters Placebo (mean±SD*)
(n=18)
Treatment (mean±SD)
(n=16)
P value
Hip (Cm) 102.16±8.58 107.25±5.81 0.055
Waist (Cm) 92.22±12.05 101.37±7.64 0.012
Weight (Kg) 68.55±7.95 74.56±9.95 0.064
Height (Cm) 158.72±7.59 163.56±9.08 0.105
WHR** 0.90±.08 0.94±.05 0.529
BMI (Kg/Cm2)*** 27.24±2.73 27.97±3.81 0.096
*Standard Deviation; **Waist to Hip Ratio; ***Body Mass Index
Table 2: The mean parameters in placebo and treatment groups
Parameters Placebo group 
mean±SE before 
intervention
Plecebo group 
mean±SE
after intervention
Treatment group 
mean±SE
before intervention
Treatment group 
mean±SE
after intervention
P value in 
plecebo 
group
P value in 
treatment 
group
FBG (mg/dl) 149.83±14.06 162.67±16.38 158.56±13.70 158.69±16.38 0.27 0.99
TG (mg/dl) 178.66±16.50 190.94±18.52 182.18±14.15 172.56±20.61 0.39 0.56
Chol (mg/dl) 172.72±11.49 184.83±13.07 185.56±10.12 191.25±10.22 0.10 0.45
LDL-C (mg/dl) 92.72±7.28 97.44±7.75 101.06±6.91 103.88±7.06 0.26 0.54
HDL-C (mg/dl) 40.89±2.82 43.44±3.39 41.38±1.97 42.94±1.91 0.14 0.28
Insulin (ng/ml) 0.25±0.02 0.25±0.02 0.41±0.16 0.35±0.11 1.000* 0.430*
MDA (µmol/L) 4.28±0.34 4.63±0.47 5.09±0.53 4.24±0.44 0.948* 0.301*
IL-6 (pg/ml) 4.38±0.80 3.09±0.43 4.51±0.45 3.83±0.35 0.038* 0.105*
hs-CRP (ng/ml) 2178.56±410.16 4060.30±1199.59 3174.87±701.77 4333.81±1256.6 0.071* 0.196*
Insulin action
QUICKI1 0.1740±0.05281 0.1725±0.04821 0.0991±0.09542 0.1152±0.09006 0.96 0.77
HOMA IR2 1.7494±0.3042 1.8793±0.3151 2.9181±1.2697 2.2061±0.6598 0.37* 0.37*
FIRI3 1.5744±0.2738 1.6913±0.2836 2.6262±1.1428 1.9855±0.5938 0.37* 0.37*
Bennett’s Index4 0.3010±0.0252 0.2946±0.0242 0.2602±0.0415 0.2716±0.0407 0.70 0.68
Ins/gluc ratio5 0.0019±0.0002 0.0018±0.0002 0.0030±0.0010 0.0028±0.0009 0.52* 0.37*
*Non-parametric Wilcoxon on signed ranks test; Insulin-sensitivity measure: 1QUICKI (quantitative insulin sensitivity check 
index): 1/log (glucose0 (mg/dl))+log (insulin0 (mU/ml)); Insulin-resistance measures: 2HOMA IR (homeostasis model for insulin 
resistance): Insulin0(mU/ml)×glucose0 (mmol/l)/22.5, 3FIRI (fasting insulin-resistance index): Insulin0 (mU/ml)×glucose0 
(mmol/l)/25, 4Bennetts index: 1/log (glucose0 (mmol/l))×log (insulin0 (mU/ml)), 5Insulin/glucose: Insulin0 (mU/ml)-to-glucose0 
(mmol/l) ratio
41 
Probiotics consumption effects on patients with type 2 diabetes
Iran J Med Sci March 2013; Vol 38 No 1
natural and safe solution to control and delay these 
complications. A strong association has been found 
between the level of oxidative stress and risk of 
cardiovascular disease. Oxidative stress not only 
causes much pathopysiological complication but 
is also linked to insulin resistance which in turn 
causes diminished glucose uptake and disposal 
in peripheral tissues, and increasing glucose 
production in the liver. It has also been reported 
that postprandial hyperlipidemia and hyperglycemia 
are associated with increasing LDL-C oxidation and 
higher risk for cardiovascular disease.4
Studies showed that probiotic containing foods 
may reduce the concentration of serum lipid and 
decreases both fasting and postprandial blood 
sugars in human.16,17 Mann and Spoerry reported 
that lactic acid bacteria are associated with a 
marked reduction in the total serum cholesterol.17 
Yun si et al, reported a significant reduction in 
fasting and postprandial glucose and decreasing 
HbA1c in probiotic (BNR17) treated rats.18
In the present study, we were not able to 
demonstrate any significant effect on fasting 
blood glucose after treating with probiotics. 
Serum triglyceride concentration was decreased 
but the change was not statistically significant. 
The reasons for these unexpected results can be 
related to either the small sample size or short 
duration of the study. 
Gilliland et al. observed some strains 
of Lactobacillus acidophilus may decrease 
cholesterol absorption by enhancing the binding 
of cholesterol to the intestinal lumen.19 Other 
possible cholesterol lowering properties of 
probiotics are deconjugation of bile by bile salt 
hydrolyses, binding of cholesterol to cellular 
surface and coprecipitation of cholesterol with 
deconjugated bile.20 This study showed no 
significant improvement in serum total cholesterol, 
LDL-cholesterol and or HDL-cholesterol after 
treating diabetic patients with probiotics.
Yadav et al. in their study on diabetic rats 
reported a marked reduction in pancreatic tissue 
oxidative damage due to a significant decrease 
in lipid peroxidation.21 In another study the same 
investigators showed that probiotic dahi not only 
decreases oxidative damage but also increases 
the antioxidant content and activities of catalase, 
glutathione peroxidase and superoxide dismutase 
in diabetic rats.22
The mechanism by which oxidative stress 
results in diabetic complications and tissue 
damage is the overproduction of the reactive 
oxygen species and reduction of the antioxidant 
defense function of the body. Lipid peroxidation 
is one of the main biological targets of oxidative 
stress, which leads to formation of secondary 
products such as malondialdehyde that 
exacerbates oxidative damage. MDA has been 
found to significantly increase in pathological 
conditions,23 which is considered as a common 
oxidative stress biomarker in recent years. 
The present study, showed a reduction in MDA 
levels in probiotic-treated group; however, the 
reduction was not statistically significant. Ejtahed 
et al.24 showed a significant reduction in blood 
glucose and MDA level in type 2 diabetic patients 
after consuming probiotic yogurt. Songisepp et al. 
evaluated the functional efficacy of antioxidative 
properties of probiotic in healthy subjects and 
found a significant improvement in blood total 
antioxidant activity (TAA) and total antioxidant 
status (TAS) after receiving probiotics.25 Harisa 
et al. also reported a significant decrease in MDA 
concentration after treating diabetic rats with L. 
acidophilus.26
Divergent evidence is available on the anti-
inflammatory properties of Probiotics. While 
some studies reported beneficial effect,27 others 
showed no effect at all. In this study, Interleukin-6 
(IL-6) was reduced while CRP levels were 
elevated but the change was not statistically 
significant. Marschan et al.28 examined the 
effect of probiotic bacteria on in vivo cytokine, 
antibody, and inflammatory responses in allergy-
prone infants and showed that infants receiving 
probiotic had higher plasma levels of CRP, and 
IL-10 compared with those in the placebo group. 
Hatakka et al. studied the effect of Lactobacillus 
rhamnosus GG (LGG) on rheumatoid arthritis 
(RA) patients and reported an increase in serum 
IL-1 beta after LGG treatment with no significant 
change in IL-6, TNF-alpha, Myeloperoxidase 
(MPO), and IL-10.29
 Conclusion                                                                                       
A reduction in oxidative stress and cardiovascular 
risk factor seems to be an ideal treatment strategy 
in type 2 diabetic patients. The result of this study 
demonstrated that a 6 weeks oral treatment with 
probiotics decreased the concentration of TG, MDA, 
and IL-6 level in type 2 diabetic patients; however 
the change were not statistically significant. These 
finding could warrant future studies to determine the 
therapeutic effects of probiotic on diabetic patients.
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